Abstract 79P
Background
Neoantigens, a type of tumor-specific antigens derived from non-synonymous mutations, have become attractive targets for cancer immunotherapy. Approaches targeting private neoantigens derived from mutations that are unique to individual patients’ tumors are costly, labor-intensive and could lead treatment resistance due to antigen loss during clonal evolution. By contrast, vaccines targeting public neoantigens derived from recurrent mutations in cancer driver genes could be designed as “off-the-shelf” vaccines and would be broadly applicable to many cancer patients. However, this therapeutic approach relies on the accurate selection of highly recurrent mutations and identification of immunogenic neoantigens.
Methods
Here, we developed a pipeline with both computational prediction tools and experimental validation assays, known as NEX-NEO to expedite the identification of public neoantigens in 100 patients with colorectal cancer (n=50) and lung cancer (n=50). Furthermore, we developed a robust screening assay using K562 cells expressing HLA-A*11:01 as antigen presenting cells to validate their immunogenicity.
Results
By using NEX-NEO, we constructed an off-the-shelf neoantigen panel of 67 neoantigen candidates which cover 63% and 49% of colorectal and lung cancer patients, respectively. Of the 47 candidates for HLA-A1101 ligand, we identified 23 (48%) immunogenic peptides which are capable of activating CD8 T cells to produce IFN-γ and Granzyme B in PBMC from 10 healthy donors.
Conclusions
In conclusion, our study proposed a novel pipeline for the development of off-the-shelf neoantigen vaccines that could benefit a large proportion of cancer patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Medical Genetics Institute.
Funding
Nexcalibur Therapeutics.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
204P - A radiomics strategy based on CT intra-tumoral and peritumoral regions for preoperative prediction of neoadjuvant chemoradiotherapy for esophageal cancer
Presenter: zhiyang li
Session: Poster Display
Resources:
Abstract
205TiP - IMPACT: Randomized, multicenter, phase III study evaluating the efficacy of immunotherapy (atezolizumab) plus anti-VEGF therapy (bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma (HCC)
Presenter: Tatsuya Yamashita
Session: Poster Display
Resources:
Abstract
206TiP - SIERRA: A phase IIIb, single-arm, multicentre study of tremelimumab plus durvalumab for first-line treatment of advanced unresectable hepatocellular carcinoma
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
207TiP - A two-arm randomized open-label prospective design superiority phase III clinical trial to compare the efficacy of docetaxel-oxaliplatin-capecitabine/ 5 -fluorouracil (DOC/F) followed by docetaxel versus CAPOX/mFOLFOX-7 in advanced gastric cancers
Presenter: Prabhat Bhargava
Session: Poster Display
Resources:
Abstract
212P - Mutational landscape and characteristics of ERBB2 in urothelial carcinoma
Presenter: Mingwei Li
Session: Poster Display
Resources:
Abstract
213P - Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma treated with first-line combination immunotherapies: Results from the International metastatic renal cell carcinoma database consortium (IMDC)
Presenter: Kosuke Takemura
Session: Poster Display
Resources:
Abstract
214P - Development and prospective validation of a multiplex RNA urine test for noninvasive detection and surveillance of urothelial carcinoma
Presenter: Hua Xu
Session: Poster Display
Resources:
Abstract
215P - Real-world outcomes of first-line tislelizumab plus axitinib in patients with metastatic non-clear cell renal cell carcinoma (mnccRCC)
Presenter: Pei Dong
Session: Poster Display
Resources:
Abstract
216P - Preliminary efficacy and safety results from ‘ReBirth’: A phase II study of risk-based bladder-sparing therapy for MIBC
Presenter: Yijun Shen
Session: Poster Display
Resources:
Abstract
217P - Conditional reprogramming of urine-derived bladder cancer cells: A model for precision medicine
Presenter: Yu Dong
Session: Poster Display
Resources:
Abstract